ARTICLE | Clinical News
Solvay Phase III cilansetron data
May 19, 2004 7:00 AM UTC
In a six-month Phase III study in 792 patients with diarrhea-predominant irritable bowel syndrome (IBS-D), significantly more patients receiving Solvay's cilansetron reported adequate relief of sympto...